ストックスクリーナーアプリを入手
0.2235
5.20%
0.0111
アフターアワーズ：
.23
0.0065
+2.91%
前日終値:
$0.2125
開ける：
$0.2125
24時間の取引高:
157.01K
Relative Volume:
0.06
時価総額：
$3.09M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-16.98%
1か月 パフォーマンス:
-39.43%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.2125
$0.23
1週間の範囲:
$0.207
$0.2712
52週間の値動き範囲:
$0.207
$2.57
Silexion Therapeutics Corp Stock (SLXN) Company Profile
名前
Silexion Therapeutics Corp
セクター
電話
972-8-6286005
住所
12 ABBA HILLEL ROAD, RAMAT GAN
SLXN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SLXN | 0.2235 | 3.09M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Silexion Therapeutics Corp (SLXN) 最新ニュース
SLXN Stock Plummets to 52-Week Low at $0.23 Amid Market Turbulence - Investing.com India
Silexion Therapeutics Reports Q3 2024 Financial Results and Clinical Progress - Citybuzz
SLXN stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
SLXN stock touches 52-week low at $0.27 amid market challenges By Investing.com - Investing.com South Africa
Silexion Therapeutics initiated with a Buy at Maxim - TipRanks
Form 424B3 Silexion Therapeutics - StreetInsider.com
Silexion Therapeutics Corp (SLXN) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Stock Market Recap: Silexion Therapeutics Corp (SLXN) Concludes at 0.29, a -8.91 Surge/Decline - The Dwinnex
Silexion Therapeutics to Participate in 2024 Maxim Healthcare Virtual Summit - Vancity Buzz
SLXN stock touches 52-week low at $0.4 amid market challenges By Investing.com - Investing.com South Africa
SLXN stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Check Out Silexion Therapeutics Corp (SLXN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Post-Trade Analysis: Silexion Therapeutics Corp (SLXN) Slides -13.65, Closing at 0.46 - The Dwinnex
Silexion Therapeutics Corp: Weathering Stock Market Storms with 1.78M Market Cap - The InvestChronicle
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Take off with Silexion Therapeutics Corp (SLXN): Get ready for trading - SETE News
Market Update: Silexion Therapeutics Corp (SLXN) Sees Positive Movement, Closing at 0.56 - The Dwinnex
PetVivo (OTCQB: PETV) Revolutionizes Veterinary Medicine, - openPR
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com
Silexion Therapeutics Corp (SLXN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Drones and biotechs are moving this morning 🛫 - RagingBull
siRNA candidate shows promise in preclinical studies - Investing.com
Silexion Therapeutics Unveils Promising Preclinical Data - openPR
siRNA candidate shows promise in preclinical studies By Investing.com - Investing.com UK
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies - Yahoo Finance
SLXN stock touches 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
SLXN stock touches 52-week low at $0.55 amid market challenges - Investing.com Australia
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - MSN
A new trading data show Silexion Therapeutics Corp (SLXN) is showing positive returns. - SETE News
In the Green: Silexion Therapeutics Corp (SLXN) Closes at 0.64, Up/Down -16.28 from Previous Day - The Dwinnex
SLXN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - Benzinga
Diabetic Kidney Disease Market Revenue to Expand Significantly - openPR
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com
Silexion Therapeutics announces new findings from Loder trial - TipRanks
Stanrose Mafatlal Investments and Finance Limited (STANROS.BO) Latest Stock News & Headlines - Yahoo Finance
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - Business Wire
Silexion Therapeutics sees board member resignation - Investing.com
Silexion Therapeutics sees board member resignation By Investing.com - Investing.com UK
Silexion Therapeutics Corp Announces Resignation of Ilan Shiloah as Independent Director, Member of Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee - Marketscreener.com
Emerging Precision Oncology Companies Show Promise Following Summit’s Success - Vancity Buzz
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
'We've run out of money' says bar owner as venue closes after nine months - Liverpool Echo
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Australia's Sims tops benchmark gains on positive FY25 start - XM
The Potential Rise in the Price of Symbotic Inc (SYM) following insiders activity - Knox Daily
Symbotic (NASDAQ:SYM) Stock Price Up 4.9% - Defense World
Supply@ME Capital (LON:SYME) Sets New 1-Year Low at $0.01 - Defense World
Silexion Therapeutics Corp (SLXN) 財務データ
Silexion Therapeutics Corp (SLXN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):